Loading
TLR7 is an innate immune sensor for viral RNA; the cream imiquimod switches it on to make the skin's immune cells attack superficial basal cell carcinoma. This dossier gathers the 1 product (1 approved), 5 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
An endosomal pattern-recognition receptor signalling through MyD88 to NF-kB and IRF7, driving type I interferon production.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | immune% | Immune-cell target (innate immune sensor in skin and immune cells, switched on by imiquimod): expressed on immune cells rather than on the tumour, so patient selection rests on the cancer type and, in trials, on PD-L1 or immune biomarkers. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Small molecule 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Negative | Primary nodular basal cell carcinoma of 4 to 20 mm: superficial curettage followed by imiquimod 5 per cent cream against surgical excision, with freedom from treatment failure at one year as the primary outcome and at five years as a pre-specified secondary outcome | Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent confidence interval 2.10 to 120.64), non-inferiority not concluded. | ||
ANCHOR NCT02135419 | 3 | Positive | People living with HIV aged 35 or older with biopsy-proven anal high-grade squamous intraepithelial lesions at 25 US sites: treatment of the lesions (mainly office-based ablation, with topical fluorouracil or imiquimod or excision) against active monitoring every six months, with progression to anal cancer as the primary endpoint | Progression to anal cancer 173 per 100,000 person-years with treatment against 402 with active monitoring, a 57 percent reduction (95% CI 6 to 80, p 0.03); the trial stopped early for efficacy. | |
| 3 | Positive | Histologically proven primary superficial basal cell carcinoma: methyl aminolevulinate photodynamic therapy in two sessions a week apart, against imiquimod 5 per cent cream once daily five days a week for six weeks, against fluorouracil 5 per cent cream twice daily for four weeks, with freedom from tumour at both three and twelve months as the primary outcome and a non-inferiority margin of 10 per cent | Tumour-free survival at five years 80.5 per cent with imiquimod, 70.0 per cent with fluorouracil and 62.7 per cent with methyl aminolevulinate photodynamic therapy; imiquimod beat both (hazard ratio 0.48 against photodynamic therapy and 0.65 against fluorouracil). | ||
| 3 | Negative | Primary nodular or superficial basal cell carcinoma at low-risk sites, excluding morphoeic and recurrent tumours and people with Gorlin syndrome: imiquimod 5 per cent cream once daily for six weeks (superficial) or twelve weeks (nodular) against surgical excision with a 4 mm margin, with clinical success at three years as the primary outcome and a non-inferiority margin of a relative risk of 0.87 | Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at five years 82.5 against 97.7 per cent; imiquimod was inferior, not non-inferior. | ||
| 1/2 | Recruiting | A Phase I/II Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7/8 Agonist in Patients With Selected Locally Advanced and/or Metastatic Solid Tumors | - | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Toll-like receptor 7" OR ABSTRACT:"Toll-like receptor 7" OR TITLE:"TLR7" OR ABSTRACT:"TLR7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Toll-like receptor 7 (TLR7), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/tlr7.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tlr7.json. Licence CC BY-NC 4.0.